Journey Medical Co. (NASDAQ:DERM) CEO Claude Maraoui Sells 14,905 Shares

Journey Medical Co. (NASDAQ:DERM) CEO Claude Maraoui sold 14,905 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $5.01, for a total transaction of $74,674.05. Following the sale, the chief executive officer now owns 2,052,418 shares in the company, valued at $10,282,614.18. The trade was a 0.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Claude Maraoui also recently made the following trade(s):

• On Wednesday, March 5th, Claude Maraoui sold 18,147 shares of Journey Medical stock. The shares were sold at an average price of $5.13, for a total transaction of $93,094.11.
• On Monday, March 3rd, Claude Maraoui sold 23,508 shares of Journey Medical stock. The shares were sold at an average price of $5.19, for a total transaction of $122,006.52.

Journey Medical Stock Performance

Shares of DERM stock traded down $0.14 during trading on Monday, reaching $5.00. 48,467 shares of the company’s stock traded hands, compared to its average volume of 94,373. The firm’s 50-day moving average is $4.60 and its 200 day moving average is $5.09. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 1.81. Journey Medical Co. has a 1 year low of $2.85 and a 1 year high of $6.89. The company has a market capitalization of $104.45 million, a P/E ratio of -5.32 and a beta of 0.97.

Hedge Funds Weigh In On Journey Medical

Several hedge funds have recently bought and sold shares of DERM. Cetera Investment Advisers grew its stake in Journey Medical by 21.8% during the fourth quarter. Cetera Investment Advisers now owns 13,839 shares of the company’s stock valued at $54,000 after acquiring an additional 2,478 shares in the last quarter. Nwam LLC bought a new position in shares of Journey Medical in the third quarter worth approximately $59,000. Kovitz Investment Group Partners LLC bought a new position in shares of Journey Medical in the third quarter worth approximately $66,000. Dimensional Fund Advisors LP bought a new position in Journey Medical during the fourth quarter valued at approximately $80,000. Finally, Citadel Advisors LLC bought a new stake in shares of Journey Medical in the 4th quarter worth approximately $174,000. Hedge funds and other institutional investors own 7.25% of the company’s stock.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.